MSH2 and cancer: Cumulative incidences for any cancer at 50 years in path_MLH1 carriers with truncating or missense/aberrant splicing variants were 39.5% (95% CI (34.5–44.5)) and 36.5% (95% CI (26.6–46.5)), respectively, and in path_MSH2 carriers, 35.2% (95% CI (29.3–41.1)) and 36.0% (95% CI (23.9–48.0)), respectively.